Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007;27(5B):3525-8
Date
11/02/2007Pubmed ID
17972512Scopus ID
2-s2.0-35348985425 (requires institutional sign-in at Scopus site) 40 CitationsAbstract
BACKGROUND: Angiogenesis plays an important role in endometrial carcinogenesis. We reviewed our experience with the anti-VEGF monoclonal antibody bevacizumab for the treatment of recurrent uterine neoplasms.
PATIENTS AND METHODS: A retrospective analysis of women with recurrent uterine neoplasms treated with bevacizumab was performed.
RESULTS: A total of 11 patients were identified, 9 with epithelial endometrial carcinomas and 2 with leiomyosarcomas. All patients had multi-site disease and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received bevacizumab combination therapy which was well-tolerated. Two patients had partial responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable for response. The median progression-free interval was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit (PR or SD).
CONCLUSION: Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.
Author List
Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RKAuthor
Janet Sue Rader MD Chair, Professor in the Obstetrics and Gynecology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Bevacizumab
Demography
Female
Humans
Incidence
Middle Aged
Neoplasm Recurrence, Local
Retrospective Studies
Treatment Outcome
United States
Uterine Neoplasms
